Phison's Pascari Enterprise Storage Honored with COMPUTEX Best Choice Golden Award for Breakthrough 245.76 TB Capacity
21.5.2026 08:30:00 CEST | Business Wire | Press Release
Phison Electronics (8299TT), a global leader in NAND flash controllers and storage solutions, today announced that its Pascari D206V PCIe Gen5 data center SSD has received the prestigious COMPUTEX Best Choice Golden Award, recognizing the next generation of innovation in ultra-high-capacity enterprise storage for AI and modern data center infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520865786/en/
Pascari D206V Wins COMPUTEX Best Choice Golden Award in 2026
The Pascari D206V is designed to address the growing industry challenge of efficiently scaling storage capacity for AI, cloud and data-intensive workloads without increasing operational complexity or infrastructure costs. Delivering up to 245.76 TB in a single U.2 PCIe Gen5 SSD, the D206V enables hyperscale and enterprise customers to significantly increase storage density while reducing rack footprint, power consumption and total data center OPEX.
“We are honored to receive the COMPUTEX Best Choice Golden Award and thank the organizers and judging panel for this recognition,” said K.S. Pua, Founder and CEO of Phison Electronics. “As AI and HPC deployments increase worldwide, organizations face growing demands for storage infrastructure that delivers greater density, efficiency, reliability and performance. The Pascari D206V was purpose-built for this new era of data center scale to help organizations store more, scale faster and optimize operational efficiency. This award reinforces Phison’s commitment to enable organizations to innovate through their data.”
Key Pascari D206V features and benefits include:
- Ultra-high storage density: Up to 245.76 TB in a single U.2 SSD enables organizations to consolidate infrastructure and maximize storage capacity per rack.
- Reduced data center OPEX: Up to an 8:1 capacity advantage over traditional HDD-based cold storage environments1 helps lower power consumption, cooling demands, rack space usage and overall operational costs.
- Read-optimized Gen5 performance: Up to 14 GB/s sequential read speeds and 2,625K million random read IOPS accelerate access to large-scale AI and enterprise datasets.
- Enterprise-grade reliability and protection: Features including dual-port connectivity, power loss protection (PLP), AES-256 encryption, TCG Opal 2.0, NVMe-MI management, 128 namespaces and end-to-end data path protection help ensure data integrity, security and system resiliency.
- OCP-aligned compatibility: Supports OCP Datacenter NVMe SSD specifications for streamlined deployment across hyperscale and open compute environments.
- Flexible deployment options: Available in U.2 for 245.76 TB capacity and E1.L, E3.L and E3.S form factors for all other D206V capacities to optimize density, thermal efficiency and scalability across diverse infrastructure architectures.
To explore more innovations, visit Phison’s COMPUTEX showcase, including the Pascari D206V and its latest AI storage innovations, at TaiNEX Hall 1, Booth M0411a. To learn more about the Pascari D206V, visit the Phison website.
About Phison Electronics
Phison Electronics is a global leader in NAND flash controllers and storage solutions, powering more than one in every five SSDs shipped worldwide. Phison has grown into a multi-billion-dollar company with over 4,500 employees—70% of which are dedicated to R&D – and more than 2,000 patents. The company’s innovations include aiDAPTIV+, an award-winning AI solution for affordable LLM training and inferencing on-premises, and Pascari, a portfolio of ultra-high-performance enterprise SSDs purpose-built for data-intensive workloads across AI, cloud, and hyperscale data centers.
Phison, the Phison design, the Phison logo are registered trademarks or trademarks of Phison Electronics or its affiliates in the US and/or other countries. All other marks are the property of their respective owners. Product specifications subject to change without notice. Pictures shown may vary from actual products.
Disclaimer: Many of the products and features mentioned are still in development and will be made available as they are finalized. The timeline for their release is dependent on the ongoing development and market and is subject to change.
©2026 Phison Electronics or its affiliates. All rights reserved.
1 All values provided are based on estimation. 1 TB = 1012 bytes. Sequential Performance is based on FIO on Linux, 128KB data size, with QD=32, 1 job. Random Performance is based on FIO on Linux, random read 4KB data size, random write 16KB data size, QD=128, 8 jobs. Latency is measured with random workloads based on FIO on Linux, 4KB data size, QD=1, 1 job. Power consumption (average RMS) is measured during the sequential read/write and random read/write operations performed by iometer. The results of DWPD are obtained in compliance with JESD219A standards.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260520865786/en/
Contacts
PHISON Spokesperson
Antonio Yu
TEL: +886-37-586-896 #10019
Mobile: +886-979-105-026
Email: antonioyu@phison.com
PHISON Deputy Spokesperson
Kuo-Ting Lu
TEL: +886-37-586-896 #26022
Mobile: +886-979-075-330
Email: kuoting_lu@phison.com
PHISON and PASCARI enterprise product inquiries:
sales@phison.com
sales@phisonenterprise.com
PHISON and PASCARI enterprise media inquiries:
Lynn Kelly
Lynn_kelly@phison.com
press_americas@phison.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom